Adverse Medication Events in Adults With Intellectual and Developmental Disabilities and Those Without

January 29, 2020

Recently published in the American Association on Intellectual and Developmental Disabilities (AAIDD), “Adverse Medication Events Related to Hospitalization in the United States: A Comparison Between Adults With Intellectual and Developmental Disabilities and Those Without” details the obstacles that Americans with an intellectual or developmental disability (IDD) face as it pertains to receiving and administering medication properly. Dr. Steven Erickson, PharmD, is an associate professor in the department of clinical pharmacy and author of this paper alongside Dr. Chung-Hsuen Wu, PhD, an alumni of the UM College of Pharmacy Social and Administrative Sciences graduate program.  The study finds that patients with an IDD are more likely to experience hospitalization as a result of adverse medication events than those without an IDD. Contributing factors to this disparity may include improper diagnosis due to communication barriers, complexity of treatments, and the number of medications prescribed.

An IDD can include a broad range of disabilities including, but not limited to, Autism Spectrum Disorder, Down Syndrome, and Cerebral Palsy. “It is estimated that 2-3% of the population has been diagnosed with an IDD and the seemingly small percentage can be a reason why their issues often go unnoticed”, explains Dr. Erickson, “However, 2-3% translates to millions of Americans.”

The immediate takeaway from this research is that prescribers, pharmacists, and caregivers need to be specifically trained to care for patients with an IDD as they are at a higher risk. Dr. Erickson believes that this paper will serve as the framework for what will be a more in-depth investigation into the adverse effects of polypharmacy and treatment of patients with an IDD.

Read the full paper: https://aaiddjournals.org/doi/full/10.1352/1944-7558-125.1.37

SHARE THIS ARTICLE

Latest News

Professor Amanda Garner Named Charles Walgreen, Jr. Professor

March 28, 2025

Author: Markie Heideman, Content Marketing Manager  Media Contact: Lindsay Groth, Director of Marketing and Communications, [email protected] Amanda Garner, PhD, has been named Charles Walgreen, Jr. Professor of Medicinal Chemistry, as approved by the Regents of the University of Michigan. Both The Charles Walgreen, Jr. Professorship created in December 2024 and the already-established Charles R. Walgreen, […]

Professor Shiyanbola Elected to Behavioral Medicine Fellowship

March 27, 2025

This SBM fellowship is not only a recognition of Dr. Shiyanbola’s hard work but an opportunity to mentor early-career investigators. 

Dr. Hanna Phan Selected for Excellence Award in Pediatric Pharmacy Practice

March 21, 2025

Dr. Phan’s dedication to improving pediatric health outcomes, particularly in pulmonology, and her passion for mentorship and education have earned her this prestigious honor.